BOTULINUM TOXIN A INJECTION AS FOREHEAD HYPERHYDROSIS THERAPY: A CASE REPORT

Sinta Murlistyarini, Nooryuliana Sariasmarina

Abstract


Craniofacial hyperhidrosis is a condition of excessive sweating in the head and face area, which can impact the quality of life. This condition can occur in individuals who experience emotional stress, excessive physical activity, without being accompanied by other pathogenic causes. The incidence of craniofacial hyperhidrosis is 9.41% of all cases of primary hyperhidrosis, with a predominance in males, and onset in young adults. The following reports a 28-year-old woman with complaints of excessive sweating on the face area, especially in the forehead since puberty. The complaints felt when the patient does light activities such as walking and when the patient feels stressed. Iodine starch minor test in the patient's forehead showed a positive result with purplish color. HDSS assessment shows severe hyperhidrosis results with score 3. Botulinum toxin A injection was performed on the patient and significant improvement were found. Evaluation in the 2nd and 4th weeks with iodine starch minor test on the patient’s forehead did not show a purplish color. HDSS assessment shows mild hyperhidrosis results with score 1. Botulinum toxin A injection in patients is known to be quite safe, fast, and effective with minimal side effects. Several studies mention an increase in quality of life as well as emotional and physical well-being in focal hyperhidrosis patients who received botulinum toxin A injection therapy.

Full Text:

PDF

References


Brackenrich J, Fagg C. Hyperhidrosis. [Updated 2022 Oct 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from:https://www.ncbi.nlm.nih.gov/books/NBK4

/

Nawrocki S, Cha J. The etiology, diagnosis, and management of

hyperhidrosis: A comprehensive review. J Am Acad Dermatol. 2019 Sep;81(3):657–66.

Campanati A, Martina E, Gregoriou S, Kontochristopoulos G, Paolinelli M, Diotallevi F, et al. Botulinum Toxin Type A for Treatment of Forehead Hyperhidrosis: Multicenter Clinical Experience and Review from Literature. Toxins (Basel). 2022 May 27;14(6):372.

Benson RA, Palin R, Holt PJE, Loftus IM. Diagnosis and management of hyperhidrosis. BMJ. 25 November 2013;347:f6800.

Hosp C, Naumann MK, Hamm H. Botulinum Toxin Treatment of Autonomic Disorders: Focal Hyperhidrosis and Sialorrhea. Semin Neurol. Februari 2016;36(1):20–8.

Wolosker N, Faustino CB, Silva MFA da, Campos JRM de, Kauffman P. Current treatment options for craniofacial

hyperhidrosis. J Vasc Bras. 2020;19.

Estevan FA, Wolosker MB, Wolosker N, Puech-Leão P. Epidemiologic analysis of prevalence of the hyperhidrosis. An Bras

Dermatol. 2017 Oct;92(5):630–4.

Haider A. Focal hyperhidrosis: diagnosis and management. Can Med Assoc J [Internet]. 2005 Jan 4;172(1):69–75. Available from:

http://www.cmaj.ca/cgi/doi/10.1503/cmaj.1040708

Romero FR, Haddad GR, Miot HA, Cataneo DC. Palmar hyperhidrosis: clinical, pathophysiological, diagnostic and

therapeutic aspects. An Bras Dermatol. 2016;91(6):716–25.

McConaghy JR, Fosselman D. Hyperhidrosis: Management options. Am Fam Physician. 2018;97(11):729–34.

Atkins JL, Butler PEM. Hyperhidrosis: a review of current management. Plast Reconstr Surg. Juli 2002;110(1):222–8.

Garcia-Souto F, del Boz J, ColmeneroSendra M, Polo-Padillo J. Craniofacial hyperhidrosis: Clinical characteristics and response to treatment in a cohort of 97 patients treated with oral oxybutynin.

Dermatol Ther. 2021;34(1):0–3.

Field M, Splevins A, Picaut P, van der Schans M, Langenberg J, Noort D, et al. AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients. Toxins (Basel). 2018 Dec 13;10(12):535.

Sammons JE, Khachemoune A. Axillary hyperhidrosis: a focused review. J Dermatolog Treat. 2017 Oct 3;28(7):582–90.

Doft MA, Hardy KL, Ascherman JA. Treatment of Hyperhidrosis With Botulinum Toxin. Aesthetic Surg J. 2012 Feb 1;32(2):238–44.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.